<DOC>
	<DOCNO>NCT01756625</DOCNO>
	<brief_summary>PREMIUM observational pharmaco-epidemiologic , transversal , multi-centric , prospective cohort study independent investigator . The purpose compare PFS real life PFS clinical trial determine factor impact efficacy compliance cetuximab treatment first line K-ras wild-type ( wt ) metastatic colorectal cancer .</brief_summary>
	<brief_title>PREMIUM , Observational Study</brief_title>
	<detailed_description>Retrospective study show influence factor efficacy treatment cetuximab ( nicotine , magnesium etc.. ) . No randomized study compare mode administration weekly biweekly cetuximab . What factor influence patient compliance ? Adverse event , relation doctor patient . PREMIUM attempt explore assess variable associate efficacy compliance treatment study practice France clinical management .</detailed_description>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>patient &gt; 18 year old diagnose mCRC patient na√Øve CT except adjuvant setting trated max 2 cycle CT first line mCRC without cetuximab patient receive cetuximab first line treatment associate CT patient relapse &lt; 6 month adjuvant therapy patient participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>nicotine</keyword>
	<keyword>magnesium</keyword>
</DOC>